Community Wellness HUB: Listening & Responding to Voices
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial,the SELECT trial,has revealed a potential increased risk of serious cardiovascular events – including heart attack,stroke,and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk.Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did *not* appear to offset this cardiovascular risk. The findings were consistent across various subgroups,even though some signals were more pronounced in those with prior heart failure.
| event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| Non-Fatal Stroke | 1.7% | 1.3% |
| Non-Fatal Heart Attack | 3.4% | 2.4% |
| MACE (Combined) | 6.5% | 4.9% |
Who is Affected? Understanding the Patient Population
These findings primarily concern individuals with both obesity and pre-existing cardiovascular disease. This includes those with a history of heart attack, stroke, peripheral artery disease, or established heart failure.The SELECT trial specifically excluded individuals with type 2 diabetes, meaning the results do not directly apply to this population, although further research is warranted. It’s crucial to differentiate this group from individuals using semaglutide for weight loss *without* underlying cardiovascular conditions, where the risk-benefit profile may remain favorable.
Why does This Matter? The Shifting Landscape of GLP-1 Receptor Agonists
Semaglutide, originally developed as a diabetes medication, gained widespread popularity for its significant weight loss effects. Previous trials, like STEP-CV8, suggested potential cardiovascular benefits in individuals *with* type 2 diabetes and cardiovascular disease. The SELECT trial challenges this narrative, demonstrating that in the absence of diabetes, the cardiovascular benefits may not be present, and a potential risk may emerge. This highlights the importance of considering the specific patient characteristics and underlying health conditions when prescribing these medications.